Nomura Research Institute, Ltd.
NRILY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -43.62 | 1.73 | -1.97 | 2.16 |
| FCF Yield | 0.00% | 1.46% | 1.18% | 1.35% |
| EV / EBITDA | 8,983.27 | 68.78 | 64.43 | 57.30 |
| Quality | ||||
| ROIC | 0.33% | 3.42% | 3.01% | 3.61% |
| Gross Margin | 37.98% | 36.56% | 35.46% | 37.01% |
| Cash Conversion Ratio | 0.90 | 1.89 | 1.59 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.47% | 3.27% | 3.38% | 3.55% |
| Free Cash Flow Growth | -99.67% | 46.48% | -8.00% | 40.78% |
| Safety | ||||
| Net Debt / EBITDA | 301.52 | 1.87 | 2.29 | 2.72 |
| Interest Coverage | 35.96 | 0.00 | 0.00 | 64.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,387.61 | 40.96 | 57.98 | 60.69 |